ERBB2 and neoplasm: Furthermore, the early results of the seminal PREDIX HER2 trial [NCT: 02568839]) support routine appraisal of tumour infiltrating lymphocytes given their predictive value in determining pCR [46] – such studies illustrate the emphasis on efforts to further personalise care for patients diagnosed with HER2+ breast cancer within the molecular era.